Table 2.
First treatment after first presentation at a multidisciplinary tumour conference (MTC) and survival
| Recommended treatment, na | Completed treatment, n (%) | Time from MTC to treatment, days, median | Survival at 1 year after MTC n (%)c | Survival at 1 year after first treatment n (%)c d | |
|---|---|---|---|---|---|
| Liver-directedb | 57 | 66 (48.2%) | 49 | 46 (69.7%) | 44 (66.7%) |
| Resection | 15 | 9 (6.6%) | 28 | 5 (55.6%) | 4 (44.4%) |
| Transplant | 18 | 8 (5.8%) | 398 | 8 (100%) | 8 (100%) |
| Systemic treatment | 12 | 9 (6.6%) | 32 | 5 (55.6%) | 4 (44.4%) |
| No treatment | 47 | 45 (32.8%) | n/a | 16 (35.6%) | NA |
| Any treatment | 88 | 92 (67.2%) | 49 | 64 (69.6%) | 60 (65.2%) |
a
Sum of recommended treatments may be greater than 100% as a result of multiple treatment recommendations.
b
Liver-directed therapy includes radiofrequency ablation, transarterial chemoembolization, cyberknife.
c
Percentage within treatment group.
d
Assumes those with treatment within 1 year of study end date are alive.
NA, not applicable.